Analysts See $-0.22 EPS for MEI Pharma, Inc. (MEIP)

August 13, 2018 - By Theresa Judd

Analysts expect MEI Pharma, Inc. (NASDAQ:MEIP) to report $-0.22 EPS on September, 4.They anticipate $0.10 EPS change or 83.33 % from last quarter’s $-0.12 EPS. After having $-0.16 EPS previously, MEI Pharma, Inc.’s analysts see 37.50 % EPS growth. It closed at $3.64 lastly. It is down 58.88% since August 13, 2017 and is uptrending. It has outperformed by 46.31% the S&P500.

MEI Pharma, Inc. (NASDAQ:MEIP) Ratings Coverage

Among 4 analysts covering MEI Pharma (NASDAQ:MEIP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MEI Pharma had 4 analyst reports since April 12, 2018 according to SRatingsIntel. Stifel Nicolaus upgraded MEI Pharma, Inc. (NASDAQ:MEIP) on Friday, July 27 to “Buy” rating. The rating was upgraded by Wells Fargo on Wednesday, June 6 to “Outperform”.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $255.99 million. The company??s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

More recent MEI Pharma, Inc. (NASDAQ:MEIP) news were published by: Benzinga.com which released: “Stifel Doubles Down On MEI Pharma, Considers ME-401 ‘Best-In-Class'” on July 27, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For July 27, 2018” on July 27, 2018. Streetinsider.com‘s news article titled: “MEI Pharma (MEIP) Promotes David M. Urso to COO” with publication date: July 16, 2018 was also an interesting one.

MEI Pharma, Inc. (NASDAQ:MEIP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.